Ipamorelin Research Guide: Mechanism, Pharmacokinetics & Studies

Ipamorelin stands apart in the crowded landscape of growth hormone secretagogues (GHSs) as the first peptide to demonstrate genuine selectivity for growth hormone (GH) release without significantly affecting other pituitary hormones. Since its initial characterization in the late 1990s, ipamorelin has become one of the most extensively studied synthetic peptides in neuroendocrine research. This guide provides a comprehensive examination of the published scientific literature on ipamorelin, covering its mechanism of action, pharmacokinetics, selectivity profile, and the diverse research applications that continue to generate interest in academic and preclinical settings.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belonging to the growth hormone secretagogue (GHS) class of compounds. It was first described by Raun et al. in 1998 and was identified through a systematic structure-activity study aimed at developing GH-releasing peptides with improved selectivity profiles. Unlike earlier GHSs such as GHRP-6 and GHRP-2, ipamorelin was specifically designed to stimulate GH release with minimal impact on adrenocorticotropic hormone (ACTH), cortisol, prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH).

The molecular weight of ipamorelin is approximately 711.85 Da. It is typically supplied as a lyophilized white powder and is reconstituted in bacteriostatic water for research applications. For more information on proper reconstitution techniques, see our guide on how to reconstitute peptides.

Mechanism of Action

Ghrelin Receptor (GHS-R1a) Agonism

Ipamorelin exerts its primary effects through selective agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor. This G-protein coupled receptor is expressed predominantly in the anterior pituitary gland and the hypothalamic arcuate nucleus. When ipamorelin binds to GHS-R1a on somatotroph cells in the anterior pituitary, it triggers a signaling cascade involving phospholipase C activation, inositol trisphosphate (IP3) generation, and intracellular calcium mobilization. The resulting calcium influx stimulates the exocytosis of stored GH vesicles.

What distinguishes ipamorelin from endogenous ghrelin and other synthetic GHS compounds is the precision of this interaction. While ghrelin activates GHS-R1a broadly across multiple tissues, and earlier synthetic GHSs like GHRP-6 demonstrate significant cross-reactivity with other neuroendocrine pathways, ipamorelin appears to activate GHS-R1a in a manner that preferentially stimulates GH release with remarkably little perturbation of other hormonal axes.

Synergy with GHRH Pathway

Research has demonstrated that the GH-releasing effects of GHS-R1a agonists like ipamorelin are amplified when the growth hormone-releasing hormone (GHRH) pathway is simultaneously active. This is because GHRH and GHS act through complementary intracellular mechanisms: GHRH primarily stimulates cAMP/protein kinase A signaling, while GHS-R1a agonists operate through the phospholipase C/calcium pathway. The convergence of these two signaling cascades at the somatotroph cell produces a synergistic rather than merely additive GH response.

This synergistic relationship is the scientific rationale behind the widely studied combination of ipamorelin with CJC-1295 (a GHRH analog). For a detailed examination of this combination, see our guide on CJC-1295/Ipamorelin.

Selectivity Profile: What Makes Ipamorelin Unique

The selectivity of ipamorelin was first systematically demonstrated in the landmark 1998 study by Raun et al. published in the European Journal of Endocrinology. The key findings that established ipamorelin as the “first selective growth hormone secretagogue” include:

• No significant ACTH or cortisol release: In conscious swine, ipamorelin stimulated GH release with an ED50 of 2.3 nmol/kg and an Emax of approximately 65 ng GH/mL plasma, values comparable to GHRP-6. However, unlike GHRP-6 and GHRP-2, ipamorelin did not produce ACTH or cortisol levels significantly different from those observed following GHRH stimulation alone.
• No effect on prolactin, FSH, LH, or TSH: At GH-releasing doses, ipamorelin did not significantly alter circulating levels of these pituitary hormones in any of the tested models.
• Dose-dependent GH release without ceiling effects: Ipamorelin demonstrated clean dose-response curves for GH release up to the maximal tested doses, without the plateau effects sometimes observed with other GHSs.

This selectivity profile is clinically significant in research contexts because the unwanted cortisol and ACTH release associated with GHRP-6 and GHRP-2 can confound experimental results and introduce catabolic signaling that opposes the anabolic effects of GH. Researchers investigating GH-specific pathways often prefer ipamorelin precisely because it allows them to isolate GH-mediated effects without the noise introduced by parallel hormonal changes.

Comparison with Other GH Secretagogues

Parameter	Ipamorelin	GHRP-6	GHRP-2	Hexarelin
GH release potency	High	High	Very High	Very High
ACTH/cortisol release	Negligible	Moderate	Moderate	High
Prolactin release	Negligible	Mild	Moderate	Moderate
Appetite stimulation	Minimal	Strong	Moderate	Mild
Receptor selectivity	High (GHS-R1a)	Low	Low-Moderate	Low
Desensitization risk	Low	Moderate	Moderate	High

For detailed guides on other GH secretagogues, see our research articles on GHRP-2, GHRP-6, and Hexarelin.

Pharmacokinetics

Human Pharmacokinetic Data

The pharmacokinetic profile of ipamorelin in humans was characterized in a dose-escalation study by Gobburu et al. (1999) involving healthy male volunteers. Subjects received intravenous infusions of ipamorelin at five dose levels (4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes). The key pharmacokinetic parameters reported were:

Parameter	Value	Notes
Terminal half-life (t1/2)	~2 hours	IV administration
Clearance (CL)	0.078 L/h/kg	Dose-proportional
Volume of distribution (Vss)	0.22 L/kg	Suggests limited tissue distribution
Time to peak GH (Tmax)	~0.67 hours (~40 min)	Rapid onset
EC50 for GH stimulation	214 nmol/L	Concentration for half-maximal effect
Maximum GH production rate	694 mIU/L/h	At saturating concentrations

The pharmacokinetic data demonstrated dose-proportionality across the tested range, meaning that doubling the dose produced a roughly proportional increase in plasma concentrations. The relatively short half-life of approximately 2 hours means that ipamorelin produces a discrete, pulsatile GH release pattern rather than sustained GH elevation, which more closely mimics the physiological pattern of endogenous GH secretion.

Pharmacokinetic Evaluation Across Delivery Routes

A separate pharmacokinetic evaluation by Johansen et al. (1999) examined ipamorelin absorption via different routes, including nasal administration. The bioavailability following nasal delivery was found to be measurable but substantially lower than parenteral administration, suggesting that subcutaneous or intravenous injection remains the preferred route for research applications requiring predictable and consistent GH responses.

Research Applications

Bone Metabolism and Skeletal Research

One of the most developed areas of ipamorelin research involves its effects on bone metabolism. Multiple preclinical studies have investigated the peptide’s potential to influence bone formation and mineralization:

• Longitudinal bone growth: Johansen et al. (1999) demonstrated that ipamorelin administration induced longitudinal bone growth in rats, with effects mediated through GH-dependent IGF-1 signaling.
• Bone mineral content: Hansen et al. (2000) reported that ipamorelin and GHRP-6 both increased tibial and vertebral bone mineral content in adult female rats treated for 12 weeks at 0.5 mg/kg/day.
• Glucocorticoid-induced bone loss: Andersen et al. (2001) demonstrated that ipamorelin counteracted the decrease in bone formation markers caused by glucocorticoid treatment in adult rats. This finding is particularly significant because glucocorticoid-induced osteoporosis is a common clinical challenge, and GH/IGF-1 pathway activation represents a potential therapeutic avenue being explored in research.

Gastrointestinal Motility Research

Ipamorelin has been investigated for its effects on gastrointestinal motility, given the established role of ghrelin and GHS-R1a signaling in gut function:

• Preclinical postoperative ileus models: Greenwood-Van Meerveld et al. (2007) showed that ipamorelin accelerated gastric emptying in a rodent model of postoperative ileus through GHS-R1a-mediated activation of cholinergic excitatory neurons.
• Clinical trial: A phase 2, randomized, double-blind, placebo-controlled trial (Lall et al., 2014) evaluated IV ipamorelin (0.03 mg/kg twice daily for up to 7 days) in 117 patients following bowel resection surgery. The peptide was well tolerated, though the primary efficacy endpoints did not reach statistical significance in this trial. The trial demonstrated the safety profile of ipamorelin in a clinical setting.

Body Composition Research

The GH-releasing properties of ipamorelin have led to its study in the context of body composition. Growth hormone is a key regulator of lipid metabolism, stimulating lipolysis and fatty acid oxidation while promoting lean tissue preservation. Preclinical studies have examined ipamorelin’s effects on body composition parameters, with several showing increases in lean body mass and decreases in adipose tissue in animal models receiving chronic ipamorelin administration. A 2020 review by Sinha et al. in the context of hypogonadal males discussed the potential role of GHS compounds including ipamorelin in body composition management.

Sleep and Circadian GH Research

Endogenous GH secretion follows a circadian pattern, with the largest secretory pulse occurring during slow-wave sleep. Research has examined how exogenous GHS administration interacts with this rhythm. Due to ipamorelin’s clean GH-specific profile, it has been used in studies investigating the relationship between GH secretion and sleep architecture without the confounding cortisol effects that would accompany GHRP-6 or hexarelin administration.

Dosing Parameters Reported in Research Studies

The following table summarizes dosing parameters reported across published ipamorelin research. These are provided for reference purposes only and represent the experimental protocols described in peer-reviewed publications.

Study	Model	Route	Dose	Duration	Primary Endpoint
Raun et al. (1998)	Swine	IV	1-30 nmol/kg	Single dose	GH release, ACTH, cortisol
Gobburu et al. (1999)	Human volunteers	IV infusion	4.21-140.45 nmol/kg	Single 15-min infusion	PK/PD modeling
Johansen et al. (1999)	Rats	SC	0.1-1 mg/kg/day	15 days	Longitudinal bone growth
Hansen et al. (2000)	Female rats	SC	0.5 mg/kg/day	12 weeks	Bone mineral content
Andersen et al. (2001)	Adult rats	SC	0.5 mg/kg/day	4 weeks	Bone formation vs. glucocorticoid
Lall et al. (2014)	Humans (Phase 2)	IV	0.03 mg/kg BID	Up to 7 days	Postoperative ileus recovery

Ipamorelin in Combination Research

Ipamorelin + CJC-1295 (No DAC)

The combination of ipamorelin with CJC-1295 without DAC (also called Modified GRF 1-29) is one of the most frequently studied GHS pairings. The rationale is straightforward: CJC-1295 No DAC acts as a GHRH analog stimulating GH synthesis and release through the cAMP pathway, while ipamorelin amplifies this signal through the complementary GHS-R1a/calcium pathway. The result is a synergistic GH pulse that exceeds what either peptide produces alone. For detailed information on CJC-1295 No DAC as a standalone compound, see our CJC-1295 No DAC research guide.

Ipamorelin vs. Sermorelin

Both ipamorelin and sermorelin are used in GH-related research, but they act through entirely different receptors. Sermorelin is a GHRH analog that activates the GHRH receptor (GHRH-R) on somatotrophs, while ipamorelin activates GHS-R1a. In research settings, the choice between the two depends on the specific pathway being investigated. Sermorelin is preferred when studying GHRH-R signaling, while ipamorelin is preferred for GHS-R1a studies or when cortisol-free GH stimulation is required.

Comparison with Tesamorelin

Tesamorelin is another GHRH analog that, like sermorelin, acts through the GHRH receptor rather than GHS-R1a. Tesamorelin has been specifically studied in the context of visceral adipose tissue reduction. Researchers comparing GH-pathway interventions may use tesamorelin as a GHRH-pathway reference and ipamorelin as a GHS-pathway reference to dissect the relative contributions of each signaling axis.

Safety and Tolerability in Published Research

Across published studies, ipamorelin has demonstrated a favorable safety and tolerability profile:

• The Gobburu et al. (1999) human PK study reported no serious adverse events across the dose range tested.
• The Lall et al. (2014) Phase 2 clinical trial in 117 postoperative patients found ipamorelin to be well tolerated, with adverse event rates comparable to placebo.
• A 2017 comprehensive review of GHS safety and efficacy by Sinha et al. in Sexual Medicine Reviews concluded that GH secretagogues as a class appear safe in available study data, though long-term safety data remain limited. Mild, transient side effects reported in some studies include injection site reactions, transient flushing, and minor headache.

The absence of significant cortisol and ACTH stimulation is considered a notable safety advantage over other GHSs, as chronic cortisol elevation is associated with a range of metabolic and immunological consequences that could complicate research outcomes.

Storage and Handling Considerations

Ipamorelin is typically supplied in lyophilized form and should be stored at -20°C for long-term stability. Once reconstituted in bacteriostatic water, it should be refrigerated at 2-8°C and used within a timeframe consistent with the peptide’s stability in solution. Reconstituted peptides are generally more susceptible to degradation than their lyophilized counterparts. For comprehensive guidance on peptide storage, see our article on how to store peptides properly.

Ipamorelin is available for research purposes at NorthPeptide.

Summary of Key Research References

Study	Year	Type	Focus	Reference
Raun et al.	1998	Preclinical	First characterization of ipamorelin as selective GHS; GH release without ACTH/cortisol effects	PMID 9849822
Gobburu et al.	1999	Clinical (Phase 1)	PK/PD modeling in healthy human volunteers; half-life, clearance, dose-response	PMID 10496658
Johansen et al.	1999	Preclinical	Longitudinal bone growth induction in rats	PMID 10373343
Johansen et al.	1999	Preclinical	PK evaluation across delivery routes including nasal administration	PMID 9879640
Hansen et al.	2000	Preclinical	Bone mineral content increase in adult female rats	PMID 10828840
Andersen et al.	2001	Preclinical	Counteracting glucocorticoid-induced bone loss	PMID 11735244
Greenwood-Van Meerveld et al.	2007	Preclinical	Gastric motility in rodent postoperative ileus model	PMID 19289567
Lall et al.	2014	Clinical (Phase 2 RCT)	Ipamorelin for postoperative ileus in bowel resection patients	PMID 25331030
Sinha et al.	2020	Review	GH secretagogues in body composition management	PMC7108996
Sigalos & Pastuszak	2017	Review	Safety and efficacy of growth hormone secretagogues	PMC5632578

Written by NorthPeptide Research Team

---

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research. It does not constitute medical advice, treatment recommendations, or an endorsement for any therapeutic purpose. The research discussed herein is predominantly preclinical, and results may not translate to human outcomes. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving these compounds.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes.